{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:18:50Z","timestamp":1790893130305,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejim.2024.01.030","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T11:45:30Z","timestamp":1706874330000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5642","authenticated-orcid":false,"given":"M.C.","family":"van Hooff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9410-781X","authenticated-orcid":false,"given":"E.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejim.2024.01.030_bib0001","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0002","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a US community","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0003","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0004","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.ejim.2024.01.030_bib0005","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"issue":"10003","key":"10.1016\/j.ejim.2024.01.030_bib0007","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0008","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0009","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0011","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.21583","article-title":"A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis","volume":"45","author":"Oertelt","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0012","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.ejim.2024.01.030_bib0013","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0015","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29717","article-title":"Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history","volume":"67","author":"Murillo Perez","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0016","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0017","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0018","first-page":"223","article-title":"Primary biliary cirrhosis: natural history","volume":"73","author":"Tornay","year":"1980","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0019","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0016-5085(90)90968-7","article-title":"Symptom development and prognosis in primary biliary cirrhosis: a study in two centers","volume":"99","author":"Mitchison","year":"1990","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.ejim.2024.01.030_bib0020","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrgastro.2015.187","article-title":"Primary biliary cirrhosis: renaming primary biliary cirrhosis-clarity or confusion?","volume":"12","author":"Trivedi","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0021","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2024.01.030_bib0022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bpg.2018.06.007","article-title":"Symptoms of PBC - pathophysiology and management","volume":"34-35","author":"Khanna","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0023","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17474124.2021.1844565","article-title":"Managing cognitive symptoms and fatigue in cholestatic liver disease","volume":"15","author":"Phaw","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0024","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cld.2022.06.009","article-title":"Evaluation and management of pruritus in primary biliary cholangitis","volume":"26","author":"Dull","year":"2022","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"10.1016\/j.ejim.2024.01.030_bib0026","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"issue":"22","key":"10.1016\/j.ejim.2024.01.030_bib0027","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0028","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0029","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.gcb.2010.07.018","article-title":"The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis","volume":"35","author":"Kuiper","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0031","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","article-title":"Characterisation of patients with a complete biochemical response to ursodeoxycholic acid","volume":"36","author":"Jorgensen","year":"1995","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0032","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0033","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.510290444","article-title":"Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression","volume":"29","author":"Degott","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0034","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Pares","year":"2000","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0035","first-page":"1148","article-title":"Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?","volume":"23","author":"Kilmurry","year":"1996","journal-title":"Hepatology"},{"issue":"9184","key":"10.1016\/j.ejim.2024.01.030_bib0036","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejim.2024.01.030_bib0037","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.ejim.2024.01.030_bib0038","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.ejim.2024.01.030_bib0039","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0040","article-title":"Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis","volume":"3","author":"Saffioti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0041","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.ejim.2024.01.030_bib0042","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/gutjnl-2019-319057","article-title":"Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis","volume":"69","author":"Harms","year":"2020","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0043","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/hepr.13880","article-title":"Quality of life in Dutch patients with primary biliary cholangitis: discrepancies between patients' perspectives and objective disease parameters","volume":"53","author":"de Veer","year":"2023","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0044","article-title":"Critical shortfalls in the management of PBC: results of a UK-wide, population-based evaluation of care delivery","volume":"6","author":"Abbas","year":"2024","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0045","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/hep.510280601","article-title":"Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications","volume":"28","author":"Beuers","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0046","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hep.510290116","article-title":"Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis","volume":"29","author":"Pasha","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0047","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000551.pub2","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gong","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ejim.2024.01.030_bib0048","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0049","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.23637","article-title":"American Association for the study of liver diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis","volume":"52","author":"Silveira","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0051","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0052","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0053","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0054","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.ejim.2024.01.030_bib0055","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0056","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease","volume":"9","author":"Cortez-Pinto","year":"2021","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0057","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ejim.2024.01.030_bib0058","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/apt.17226","article-title":"Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid","volume":"56","author":"de Veer","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ejim.2024.01.030_bib0059","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.ejim.2024.01.030_bib0060","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0061","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.ejim.2024.01.030_bib0062","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0063","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: aST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0064","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0066","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2024.01.030_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0068","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2009.12.002","article-title":"The new therapeutic frontier\u2013nuclear receptors and the liver","volume":"52","author":"Karpen","year":"2010","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0069","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cld.2012.12.001","article-title":"Nuclear receptors as drug targets in cholestatic liver diseases","volume":"17","author":"Halilbasic","year":"2013","journal-title":"Clin Liver Dis"},{"issue":"17","key":"10.1016\/j.ejim.2024.01.030_bib0070","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0071","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0072","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"issue":"31","key":"10.1016\/j.ejim.2024.01.030_bib0073","doi-asserted-by":"crossref","first-page":"28857","DOI":"10.1074\/jbc.M011610200","article-title":"Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor","volume":"276","author":"Ananthanarayanan","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0074","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.20295","article-title":"Bile acid-induced negative feedback regulation of the human ileal bile acid transporter","volume":"40","author":"Neimark","year":"2004","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile Acids as Hormones: the FXR-FGF15\/19 Pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig Dis"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0076","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1096\/fba.2018-00046","article-title":"Bile acid receptor agonists in primary biliary cholangitis: regulation of the cholangiocyte secretome and downstream T cell differentiation","volume":"1","author":"Etherington","year":"2019","journal-title":"FASEB Bioadv"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0077","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0078","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0079","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jhep.2022.10.007","article-title":"Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases(dagger)","volume":"78","author":"Nevens","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.ejim.2024.01.030_bib0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic acid: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ejim.2024.01.030_bib0081","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejim.2024.01.030_bib0082","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep4.1518","article-title":"Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis","volume":"4","author":"Roberts","year":"2020","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0083","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2022.07.038","article-title":"UK-wide multicenter evaluation of second-line therapies in primary biliary cholangitis","volume":"21","author":"Abbas","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0084","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D'Amato","year":"2021","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/apt.16181","article-title":"Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid","volume":"53","author":"Gomez","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl 1","key":"10.1016\/j.ejim.2024.01.030_bib0086","article-title":"Long-term efficacy and safety of obeticholic acid in primary biliary cholangitis: responder analysis of more than 5 years of treatment in the POISE trial [AASLD abstract 1251]","volume":"72","author":"Hansen","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejim.2024.01.030_bib0087","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0088","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/hep4.1180","article-title":"Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis","volume":"2","author":"Carbone","year":"2018","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0089","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2024.01.030_bib0090","unstructured":"US Food and Drug Administration. Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis. https:\/\/wwwfdagov\/drugs\/drug-safety-and-availability\/due-risk-serious-liver-injury-fda-restricts-use-ocaliva-obeticholic-acid-primary-biliary-cholangitis.Accessed August 2023."},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0091","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2024.01.030_bib0092","article-title":"The Nonsteroidal Farnesoid X Receptor (FXR) agonist cilofexor improves liver biochemistry in patients with Primary Biliary Cholangitis (PBC): a phase 2, randomized, placebo-controlled trial","volume":"70","author":"KV","year":"2019","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.ejim.2024.01.030_bib0093","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0094","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12876-023-02653-2","article-title":"PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis","volume":"23","author":"Trauner","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ejim.2024.01.030_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J Transl Autoimmun"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0097","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","article-title":"Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis","volume":"16","author":"Iwasaki","year":"1999","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0098","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MOG.0000000000000056","article-title":"Fibrate treatment for primary biliary cirrhosis","volume":"30","author":"Cuperus","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.ejim.2024.01.030_bib0099","article-title":"Fibrates for the treatment of primary biliary cholangitis unresponsive to ursodeoxycholic acid: an exploratory study","volume":"12","author":"Cancado","year":"2021","journal-title":"Front Pharmacol"},{"issue":"23","key":"10.1016\/j.ejim.2024.01.030_bib0100","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejim.2024.01.030_bib0101","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/apt.16618","article-title":"Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up","volume":"54","author":"Sorda","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0102","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0103","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: a Double-Blind, Randomized, Placebo-Controlled Trial","volume":"160","author":"de Vries","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0104","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/liv.14871","article-title":"Safety of fibrates in cholestatic liver diseases","volume":"41","author":"Carrion","year":"2021","journal-title":"Liver Int"},{"issue":"21","key":"10.1016\/j.ejim.2024.01.030_bib0105","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.030_bib0106","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0107","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.ejim.2024.01.030_bib0108","article-title":"Results of the first national audit of PBC management reveal significant variation in care delivery across the UK","volume":"71","author":"Smith","year":"2022","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.ejim.2024.01.030_bib0109","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ejim.2024.01.030_bib0110","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0111","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0112","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0113","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0114","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0115","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/HEP.0000000000000018","article-title":"Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration","volume":"77","author":"Diaz-Gonzalez","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8278(96)80327-8","article-title":"Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis","volume":"25","author":"Leuschner","year":"1996","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0117","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"11\u201312","key":"10.1016\/j.ejim.2024.01.030_bib0118","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1365-2036.2006.03155.x","article-title":"Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis","volume":"24","author":"Rautiainen","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ejim.2024.01.030_bib0119","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/apt.15528","article-title":"Adverse events related to low dose corticosteroids in autoimmune hepatitis","volume":"50","author":"van den Brand","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2024.01.030_bib0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/CEG.S204638","article-title":"Osteoporosis in primary biliary cholangitis: prevalence, impact and management challenges","volume":"13","author":"Trivedi","year":"2020","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.030_bib0121","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2024.01.030_bib0122","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.030_bib0123","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J Hepatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T15:38:15Z","timestamp":1717515495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":123,"alternative-id":["S0953620524000372"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.01.030","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}